Hypertension is the most prevalent cardiovascular condition among older adults and a major contributor to morbidity, disability, and mortality worldwide. The progressive rise in life expectancy has led to a growing population of elderly patients with unique physiological changes, comorbidities, and treatment challenges. Unlike younger populations, older adults often present with isolated systolic hypertension, increased arterial stiffness, and a greater susceptibility to adverse drug effects, necessitating tailored therapeutic strategies.

This narrative review summarizes the current understanding of hypertension management in the elderly, with emphasis on epidemiology, pathophysiology, clinical features, and treatment goals. Non-pharmacological interventions, including dietary modification, physical activity, and sodium restriction, remain fundamental components of management. Pharmacological therapy requires careful agent selection and titration to minimize risks such as orthostatic hypotension, electrolyte imbalance, and polypharmacy-related interactions. Evidence from landmark clinical trials, including HYVET and SPRINT, has demonstrated the benefit of blood pressure reduction in older adults, though optimal targets remain debated.

Special considerations such as frailty, cognitive impairment, and multimorbidity are crucial in guiding individualized care. Adherence and follow-up are often compromised in this population, highlighting the need for multidisciplinary approaches and patient-centered strategies. Future directions include the integration of telemedicine, wearable technologies, pharmacogenomics, and artificial intelligence into routine practice, offering opportunities for personalized risk stratification and improved outcomes.

In conclusion, hypertension in the elderly requires a delicate balance between efficacy and safety. An evidence-based, holistic, and individualized approach is essential to reduce cardiovascular risk while preserving quality of life in aging populations. Ongoing research and health policy efforts are needed to ensure equitable and effective hypertension care worldwide.

Keywords: hypertension, elderly patients, antihypertensive therapy, cardiovascular risk

Hypertension is one of the most prevalent chronic conditions worldwide, representing a leading cause of cardiovascular morbidity and mortality across all age groups. However, its clinical significance is particularly pronounced in the elderly, where it contributes substantially to the risk of stroke, heart failure, myocardial infarction, chronic kidney disease, and cognitive decline.¹ The global demographic shift toward an aging population has further amplified the importance of managing hypertension in older adults. It is estimated that more than two-thirds of individuals over 65 years of age are hypertensive, making it the most common chronic condition in this age group.²

Unlike younger adults, elderly patients exhibit unique pathophysiological characteristics that influence both the development of hypertension and the therapeutic approach. Age-related vascular changes, such as increased arterial stiffness, reduced baroreceptor sensitivity, and alterations in renal function, not only elevate blood pressure but also modify the hemodynamic response to antihypertensive treatment.³ Furthermore, older adults frequently present with multimorbidity and frailty, complicating treatment decisions and highlighting the importance of individualized management strategies.

The therapeutic goals in elderly patients must balance the benefits of blood pressure reduction against the risks of overtreatment, including orthostatic hypotension, falls, and drug-related adverse effects.⁴ Current international guidelines reflect this complexity, with age-specific targets and recommendations that often differ from those for younger populations. Moreover, the heterogeneity among elderly patients—from the relatively healthy “young-old” (65–74 years) to the frail “old-old” (≥85 years)—necessitates a nuanced approach to care.

The aim of this review is to provide a comprehensive overview of hypertension management in elderly patients, focusing on the epidemiology, pathophysiological mechanisms, diagnostic challenges, treatment strategies, and evidence from major clinical trials. In particular, differences from younger populations will be emphasized to highlight the distinct considerations required in this vulnerable group. This review also aims to critically analyze both the persistent challenges and the emerging advances in the management of hypertension in elderly patients, providing a bridge between traditional approaches and innovative solutions.

A narrative literature review was conducted to identify publications related to hypertension management in elderly patients. Searches were performed in PubMed, Scopus, and Web of Science databases using combinations of keywords such as “elderly hypertension,” “frailty,” “pharmacological management,” “non-pharmacological interventions,” and “emerging technologies.” Articles published in English between 2000 and 2024 were considered. Studies focusing on elderly populations or providing age-specific analyses were prioritized, while case reports and non-peer-reviewed sources were excluded. Relevant clinical guidelines and landmark clinical trials were also included to ensure comprehensive coverage of current evidence.

The aging process induces a series of structural and functional alterations in the cardiovascular and renal systems that significantly impact blood pressure regulation. One of the most prominent changes is increased arterial stiffness, largely driven by progressive loss of elastin and accumulation of collagen within the vascular wall. This results in elevated systolic blood pressure, widened pulse pressure, and the development of isolated systolic hypertension, a hallmark of hypertension in older adults.⁵

Another important alteration is the decline in baroreceptor sensitivity. With age, baroreflex-mediated adjustments to blood pressure become blunted, reducing the ability to maintain hemodynamic stability during postural changes or stress. This contributes to a higher prevalence of orthostatic hypotension in elderly individuals, which in turn increases the risk of dizziness, falls, and subsequent morbidity.⁶

Renal aging also plays a central role. There is a gradual reduction in renal blood flow, glomerular filtration rate, and sodium excretion capacity, leading to increased salt sensitivity and impaired volume regulation.⁷ These changes predispose elderly patients to both hypertension and adverse effects from antihypertensive therapies, such as electrolyte disturbances and acute kidney injury.

In addition, autonomic nervous system function undergoes important shifts. Sympathetic nervous system activity tends to increase with age, while parasympathetic tone declines, resulting in greater vascular resistance and higher blood pressure variability.⁸ These changes contribute not only to the pathogenesis of hypertension but also to the heightened cardiovascular risk observed in this population.

Pharmacokinetics and pharmacodynamics are also markedly altered in elderly individuals. Reduced hepatic metabolism, decreased renal clearance, and changes in body composition (e.g., increased fat mass, reduced lean body mass) alter the distribution and elimination of antihypertensive drugs.⁹ Consequently, older adults may demonstrate exaggerated responses to standard drug doses, reinforcing the principle of “start low, go slow” in this age group.

In contrast to younger adults, where hypertension is often associated with increased cardiac output and peripheral vascular resistance, hypertension in elderly patients is predominantly characterized by vascular stiffness and impaired regulatory mechanisms. This distinction is crucial for tailoring treatment approaches that minimize harm while ensuring adequate blood pressure control.

Epidemiology and risk factors

Hypertension is the most common chronic condition in the elderly population, with prevalence rates exceeding 60–70% among individuals aged 65 years and older.¹⁰ Epidemiological data from both developed and developing countries consistently demonstrate a steep rise in hypertension prevalence with advancing age, largely driven by vascular aging, renal impairment, and cumulative exposure to cardiovascular risk factors.¹¹ Importantly, the lifetime risk of developing hypertension is estimated to be greater than 90% for individuals who live into their 80s, underscoring the near inevitability of hypertension in later life.¹²

Sex differences also play a role in epidemiology. While men tend to develop hypertension earlier in life, the prevalence in women surpasses that of men after menopause, likely due to hormonal changes, weight gain, and increased arterial stiffness.¹³ Consequently, older women face a particularly high burden of hypertension-related complications, including stroke and heart failure with preserved ejection fraction.

Comorbidity is another defining feature of hypertension in elderly patients. Conditions such as diabetes mellitus, chronic kidney disease, coronary artery disease, chronic obstructive pulmonary disease, and dementia are frequently coexistent, complicating both diagnosis and treatment.¹⁴ The interplay between hypertension and multimorbidity not only increases cardiovascular risk but also raises concerns about polypharmacy, drug–drug interactions, and treatment adherence.

Lifestyle and socioeconomic determinants further contribute to the risk of hypertension in the elderly. Sedentary behavior, unhealthy diet, obesity, and excessive alcohol intake are modifiable factors that continue to exert influence even in later decades of life.¹⁵ Moreover, social isolation, low income, and limited access to healthcare services exacerbate the prevalence and consequences of uncontrolled hypertension in older adults, particularly in low-resource settings.

Compared with younger individuals, hypertension in the elderly tends to present with a higher systolic component, greater prevalence of isolated systolic hypertension, and a stronger association with end-organ damage. These distinctions highlight the need for age-specific preventive strategies that target both biological and social determinants of health.

Clinical characteristics and diagnostic considerations

Hypertension in elderly patients often presents with distinctive clinical features compared to younger adults. While many individuals remain asymptomatic, some may experience nonspecific complaints such as dizziness, headaches, or fatigue, which are frequently attributed to aging itself rather than elevated blood pressure. More importantly, hypertension in this population is strongly linked with end-organ damage, including left ventricular hypertrophy, chronic kidney disease, and cerebrovascular disease, which may manifest as cognitive decline or functional impairment.¹⁶

Blood pressure measurement in older adults presents unique challenges. Orthostatic hypotension, defined as a drop in systolic blood pressure ≥20 mmHg or diastolic blood pressure ≥10 mmHg within three minutes of standing, is particularly common due to impaired baroreflex sensitivity and autonomic dysfunction.¹⁷ This phenomenon complicates both diagnosis and treatment, as aggressive blood pressure reduction may exacerbate postural symptoms and increase the risk of falls.

The white coat effect and masked hypertension are also prevalent among elderly patients, leading to potential misclassification if diagnosis relies solely on office blood pressure measurements. Ambulatory blood pressure monitoring (ABPM) and home blood pressure monitoring (HBPM) are therefore strongly recommended to improve diagnostic accuracy, detect nocturnal hypertension, and evaluate blood pressure variability.¹⁸ These tools are especially useful in differentiating between sustained hypertension and white coat hypertension, thus avoiding unnecessary treatment or undertreatment.

Another essential aspect is the assessment of frailty and cognitive function. Frailty, characterized by decreased physiological reserve and vulnerability to stressors, significantly modifies the risk–benefit ratio of antihypertensive therapy.¹⁹ Similarly, cognitive impairment and dementia not only influence treatment goals but also affect medication adherence, highlighting the need for caregiver involvement in management.

In contrast to younger patients, where diagnosis is relatively straightforward, hypertension in elderly populations requires a multidimensional evaluation that integrates hemodynamic assessment, comorbidities, functional status, and social support. Such a comprehensive approach ensures that therapeutic strategies are both safe and effective.

Target blood pressure and guidelines

The determination of optimal blood pressure (BP) targets in elderly patients remains a subject of ongoing debate. While lowering blood pressure unequivocally reduces the risk of stroke, myocardial infarction, and heart failure, excessive reduction may increase the risk of orthostatic hypotension, falls, syncope, renal impairment, and even mortality.²⁰ Therefore, guideline recommendations emphasize individualized treatment goals based on age, comorbidities, frailty status, and overall life expectancy.

The 2017 ACC/AHA guidelines recommend initiating pharmacological therapy in patients aged ≥65 years with a systolic BP ≥130 mmHg, with a target of <130/80 mmHg for most older adults, provided treatment is well tolerated.¹ In contrast, the 2018 ESC/ESH guidelines adopt a more conservative approach: in patients aged 65–79 years, they recommend a systolic BP target of 130–139 mmHg, but not below 130 mmHg; for patients ≥80 years, treatment should generally be initiated if systolic BP is ≥160 mmHg, aiming for a target of 130–139 mmHg if tolerated² The NICE guidelines also suggest similar age-adjusted thresholds, recognizing the increased vulnerability of very old patients.²¹ 

Evidence from large clinical trials has shaped these recommendations. The HYVET trial demonstrated that antihypertensive therapy in patients aged ≥80 years reduced stroke incidence and all-cause mortality, supporting treatment even in very old patients, though with cautious targets.²² On the other hand, the SPRINT trial, which included patients ≥75 years, showed that intensive BP lowering (<120 mmHg systolic) significantly reduced cardiovascular events and mortality, but at the cost of higher adverse events such as hypotension, syncope, and electrolyte abnormalities.²³ These findings highlight the delicate balance between benefit and harm in this population.

Importantly, heterogeneity within the elderly group complicates universal recommendations. A relatively fit 70-year-old without major comorbidities may safely tolerate intensive BP control, whereas a frail 85-year-old with multiple chronic conditions may experience harm from aggressive therapy. Thus, both American and European guidelines underscore the necessity of tailoring treatment goals to the individual patient, taking into account frailty, cognitive function, and patient preferences.

In summary, compared with younger adults, elderly patients require more cautious and flexible BP targets. The overarching principle is to achieve adequate cardiovascular protection while minimizing the risks of overtreatment.

Lifestyle modifications

Lifestyle modification remains the cornerstone of hypertension management, including in the elderly. Although pharmacological therapy is often required, non-pharmacological interventions play a critical role in reducing blood pressure, enhancing drug efficacy, and minimizing cardiovascular risk. Importantly, lifestyle interventions must be adapted to the physiological limitations and comorbidities commonly observed in older adults.²⁴

Dietary modification is one of the most effective non-pharmacological strategies. The Dietary Approaches to Stop Hypertension (DASH) diet, which emphasizes fruits, vegetables, whole grains, and low-fat dairy products, has been shown to significantly lower systolic and diastolic blood pressure in elderly populations.²⁵ Sodium restriction, generally recommended at <2.3 g/day, is particularly relevant, as older adults often exhibit heightened salt sensitivity due to age-related renal changes.²⁶ Similarly, adherence to the Mediterranean diet has been associated with lower cardiovascular morbidity and improved cognitive outcomes in elderly hypertensive patients.²⁷

Physical activity is another critical component. Regular aerobic exercise such as walking, swimming, or cycling has been shown to reduce systolic blood pressure by 5–10 mmHg, even in older individuals.²⁸ However, exercise programs must be carefully tailored to functional status, frailty, and comorbidities to avoid falls or musculoskeletal injuries. Strength and balance training also confer additional benefits by reducing fall risk and improving mobility.

Weight management remains relevant in older hypertensive patients, particularly in those with obesity-related hypertension. Even modest weight loss has been associated with significant reductions in blood pressure and improved metabolic profile.²⁹ However, excessive or rapid weight loss should be avoided in frail elderly individuals, where sarcopenia and malnutrition may increase morbidity.

Alcohol moderation and smoking cessation are universally recommended. Excessive alcohol intake is associated with poor blood pressure control and increased risk of arrhythmias, while smoking exacerbates cardiovascular and cerebrovascular risk.³⁰ Counseling and structured cessation programs remain beneficial even at advanced ages.

Finally, psychosocial factors should not be overlooked. Stress reduction strategies, adequate sleep, and strong social engagement have all been associated with improved blood pressure control and overall health outcomes in elderly patients.³¹ Social isolation, a common problem in older age, may worsen hypertension control and adherence, highlighting the importance of holistic care approaches.

In summary, lifestyle modifications in the elderly share many principles with younger populations, but must be implemented with greater attention to comorbidities, frailty, and functional limitations. When properly adapted, these measures can provide substantial benefits, both independently and in synergy with pharmacological therapy.

Pharmacological management

Pharmacological therapy is the mainstay of hypertension treatment in the elderly, as lifestyle interventions alone are often insufficient to achieve target blood pressure. However, due to age-related physiological changes and the frequent presence of comorbidities, the choice of antihypertensive agents, dosing strategies, and monitoring require particular caution in this population.¹⁶

Thiazide and thiazide-like diuretics are among the most widely used first-line therapies for elderly hypertensive patients. Evidence from trials such as SHEP and ALLHAT demonstrated that thiazide diuretics reduce the risk of stroke and heart failure in older adults.³² They are particularly effective in isolated systolic hypertension, a common phenotype in the elderly. Nonetheless, potential side effects, including hyponatremia, hypokalemia, hyperuricemia, and worsening renal function, must be carefully monitored.

Calcium channel blockers (CCBs) are another cornerstone of therapy. They are effective in lowering systolic pressure, improving arterial compliance, and reducing cardiovascular events. The LIFE and Syst-Eur trials have highlighted their efficacy in elderly patients.³³ Peripheral edema and constipation are among the most common adverse effects, but CCBs generally demonstrate good tolerability in this age group.

Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are highly beneficial in elderly hypertensive patients, especially those with comorbid conditions such as heart failure, diabetes, or chronic kidney disease.³⁴ They provide renoprotective and cardioprotective benefits but may increase the risk of hyperkalemia and renal dysfunction, particularly in those with advanced kidney disease or concomitant potassium-sparing diuretics.

Beta-blockers are no longer considered first-line therapy for uncomplicated hypertension in the elderly but remain valuable in specific situations, such as post-myocardial infarction, atrial fibrillation, or chronic heart failure.³⁵ Their use must be weighed against risks of bradycardia, fatigue, and worsened insulin sensitivity.

Polypharmacy is a frequent challenge in elderly patients. Age-related changes in drug metabolism and elimination, combined with multiple comorbidities, increase the likelihood of drug–drug interactions and adverse effects.³⁶ Simplifying regimens through fixed-dose combinations and careful medication reconciliation are recommended strategies to improve adherence and safety. The guiding principle in pharmacological management for elderly patients is “start low and go slow,” with gradual titration and close monitoring for tolerance.

In comparison with younger adults, elderly patients often require a more cautious pharmacological approach, with emphasis on minimizing harm while achieving adequate blood pressure control. Selection of agents should be individualized, based not only on blood pressure levels but also on comorbidities, frailty status, and patient preferences (Table 1).

Hypertension management in elderly patients is further complicated by the frequent coexistence of comorbidities and geriatric syndromes. Tailoring therapy to specific clinical contexts is essential to balance cardiovascular protection with safety.³⁷

Frailty and multimorbidity: Frailty is highly prevalent among elderly patients with hypertension and is associated with increased vulnerability to adverse outcomes from both hypertension and its treatment. Evidence suggests that aggressive BP lowering in frail older adults may lead to excess risks, including orthostatic hypotension, falls, syncope, and even mortality.³⁸ The management approach in these individuals should focus on cautious BP reduction, prioritizing quality of life, functional independence, and minimization of adverse events.

Cognitive impairment and dementia: Hypertension is both a risk factor for cognitive decline and a complicating factor in dementia care. While midlife hypertension is strongly linked with later dementia risk, the benefits of late-life BP reduction on cognition are less consistent.³⁹ Excessive BP lowering may exacerbate cerebral hypoperfusion, worsening cognitive impairment. Therefore, in patients with dementia, moderate BP control is generally preferred, avoiding overly stringent targets.

Diabetes mellitus: Hypertension and diabetes frequently coexist in elderly patients, compounding cardiovascular and renal risks. Guidelines recommend the use of ACEIs or ARBs as first-line agents in elderly patients with diabetes, given their nephroprotective and cardioprotective properties.⁴⁰ However, treatment should remain individualized, with careful monitoring of renal function and electrolyte balance.

Chronic kidney disease (CKD): CKD is common in elderly hypertensive patients and requires careful management. While ACEIs and ARBs remain the preferred agents, reduced renal clearance of drugs and heightened risk of hyperkalemia necessitate vigilant monitoring.⁴¹ BP targets should aim for balance—avoiding excessive reduction that may impair renal perfusion.

Heart failure: In elderly patients with hypertension and heart failure, optimal pharmacological management includes ACEIs/ARBs, beta-blockers, and mineralocorticoid receptor antagonists, when tolerated.⁴² However, the interplay between low systolic BP and heart failure symptoms requires nuanced treatment. Diuretics may relieve congestion but can exacerbate electrolyte imbalances and renal dysfunction.

Orthostatic hypotension: Orthostatic hypotension is particularly prevalent in elderly hypertensive patients and is associated with falls, syncope, and fractures.⁴³ Careful assessment is required before and after initiating antihypertensive therapy. Long-acting medications are generally preferred to avoid wide BP fluctuations. Treatment should prioritize symptom reduction and fall prevention rather than strict BP targets.

In summary, managing hypertension in elderly patients requires individualized strategies that account for frailty, multimorbidity, and specific comorbid conditions. Compared with younger populations, the risk–benefit ratio of antihypertensive therapy in the elderly is narrower, underscoring the importance of tailoring treatment to clinical context.

Blood pressure monitoring in the elderly: Accurate blood pressure (BP) measurement is critical in elderly patients, as diagnostic and therapeutic decisions hinge upon precise assessment. However, physiological changes associated with aging introduce unique challenges that can complicate conventional BP monitoring.⁴⁴

Office blood pressure measurement: Although office-based BP measurement remains the cornerstone of hypertension diagnosis, it may be less reliable in older adults due to phenomena such as white coat hypertension and masked hypertension. White coat hypertension is particularly common in this population, potentially leading to overtreatment if relied upon exclusively. Conversely, masked hypertension, where BP is normal in clinical settings but elevated outside, is strongly associated with cardiovascular events and may remain undetected without additional monitoring.⁴⁵

Ambulatory blood pressure monitoring (ABPM): ABPM is considered the gold standard for hypertension assessment in elderly patients. It provides insights into 24-hour BP variability, nocturnal dipping patterns, and morning surges, all of which have prognostic significance. Non-dipping or reverse-dipping patterns are particularly prevalent among elderly individuals and correlate with increased risk of stroke, heart failure, and cognitive decline.⁴⁶ Moreover, ABPM can help assess treatment efficacy and detect orthostatic hypotension episodes that may otherwise go unnoticed.

Home blood pressure monitoring (HBPM): HBPM is a practical and widely recommended approach for elderly patients, especially those with mobility limitations. It empowers patients and caregivers, improves adherence to therapy, and allows repeated measurements under real-life conditions. HBPM is also valuable in distinguishing sustained hypertension from white coat hypertension and provides complementary information to ABPM.⁴⁷ However, challenges include correct device use, manual dexterity issues, and visual or cognitive impairment, which may necessitate caregiver assistance.

Hypertension in the elderly represents both a common and complex clinical challenge. With the progressive aging of the global population, the burden of hypertension-related morbidity and mortality continues to rise, underscoring the importance of optimized strategies for diagnosis, monitoring, and treatment.¹ Unlike younger populations, older adults exhibit distinct pathophysiological features such as increased arterial stiffness, widened pulse pressure, and a higher prevalence of isolated systolic hypertension. These differences necessitate tailored approaches that balance therapeutic benefits with the risks of polypharmacy, orthostatic hypotension, and treatment intolerance.

The evidence from major clinical trials has demonstrated that lowering blood pressure in elderly patients significantly reduces the risk of cardiovascular events, including stroke and heart failure.²² However, controversies remain regarding optimal targets, with individualized care being paramount. Non-pharmacological strategies, including dietary modifications, exercise, and lifestyle interventions, should complement pharmacological therapy. Pharmacologic treatment requires careful drug selection, titration, and monitoring, taking into account comorbidities, frailty, and cognitive status.

Emerging technologies, including telemedicine, artificial intelligence, and pharmacogenomic-guided therapies, offer promising avenues for more personalized and effective management in the future.⁶⁸ Furthermore, multidisciplinary approaches that incorporate cardiologists, geriatricians, primary care providers, and allied health professionals will likely become the cornerstone of hypertension care for the elderly.

Oliveros et al.⁶⁹ provided a broad overview of hypertension assessment and management in older adults, while Benetos et al.⁷⁰ highlighted the unique therapeutic challenges in frail populations. More recently, Dhiman et al.⁷¹ emphasized persistent gaps in treatment optimization and the need for individualized approaches. Collectively, these studies underscore the complexity of hypertension care in the elderly, where biological heterogeneity, frailty, and multimorbidity demand flexible and cautious management strategies. The present review expands upon these perspectives by integrating both conventional therapeutic considerations and emerging innovations, including telemedicine, wearable technologies, and pharmacogenomics. This dual focus allows for a more comprehensive understanding of how established practices can be adapted in parallel with technological advances to improve outcomes in older patients. By positioning current challenges alongside future opportunities, our work contributes to bridging the gap between evidence-based management and personalized, forward-looking care models for elderly patients with hypertension.

In summary, while significant progress has been made in understanding and managing hypertension in older adults, ongoing research, clinical innovation, and health system adaptations are required to address the unique challenges of this population. A holistic, patient-centered, and evidence-based strategy remains essential for improving outcomes and quality of life in elderly patients living with hypertension.⁷²

All of the authors contributed planning, conduct, and reporting of the work. All authors had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis

No financial funding was received for this study.

All of the authors have no conflict of interest.

1. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71(6):e13–e115.
2. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104.
3. Franklin SS, Gustin W, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. Circulation. 1997;96(1):308–315.
4. Benetos A, Petrovic M, Strandberg T. Hypertension management in older and frail older patients. Circ Res. 2019;124(7):1045–1060.
5. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Circulation. 2003;107(1):139–146.
6. Lipsitz LA. Age-related changes in the “complexity” of cardiovascular dynamics: implications for heart rate and blood pressure variability. J Gerontol A Biol Sci Med Sci. 1997;52(3):M167–M175.
7. Musso CG, Oreopoulos DG. Aging and physiological changes of the kidneys including changes in glomerular filtration rate. Nephron Physiol. 2011;119(1):p1–p5.
8. Seals DR, Esler MD. Human ageing and the sympathoadrenal system. J Physiol. 2000;528(Pt 3):407–417.
9. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14.
10. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–223.
11. Danaei G, Finucane MM, Lin JK, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet. 2011;377(9765):568–577.
12. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287(8):1003–1010.
13. Reckelhoff JF. Gender differences in hypertension. Curr Opin Nephrol Hypertens. 2018;27(3):176–181.
14. Abete P, Della-Morte D, Gargiulo G, et al. Cognitive impairment and cardiovascular diseases in the elderly: a heart–brain continuum hypothesis. Ageing Res Rev. 2014;18:41–52.
15. Lloyd-Sherlock P, Beard J, Minicuci N, et al. Hypertension among older adults in low- and middle-income countries: prevalence, awareness and control. Int J Epidemiol. 2014;43(1):116–128.
16. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly. J Am Coll Cardiol. 2011;57(20):2037–2114.
17. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope, and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69–72.
18. Head GA, Mihailidou AS, Duggan KA, et al. Ambulatory blood pressure monitoring in Australia: 2011 consensus position statement. Med J Aust. 2012;197(3):147–150.
19. Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet. 2013;381(9868):752–762.
20. Bavishi C, Bangalore S, Messerli FH. Outcomes of intensive blood pressure lowering in older hypertensive patients. J Am Coll Cardiol. 2017;69(5):486–493.
21. National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. NICE guideline [NG136]. 2019.
22. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–1898.
23. Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA. 2016;315(24):2673–2682.
24. Appel LJ, Brands MW, Daniels SR, et al. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension. 2006;47(2):296–308.
25. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344(1):3–10.
26. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension. 1996;27(3 Pt 2):481–490.
27. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14):1279–1290.
28. Cornelissen VA, Smart NA. Exercise training for blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2(1):e004473.
29. Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med. 2001;134(1):1–11.
30. Briasoulis A, Agarwal V, Messerli FH. Alcohol consumption and the risk of hypertension in men and women: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2012;14(11):792–798.
31. Hawkley LC, Cacioppo JT. Loneliness and pathways to disease. Brain Behav Immun. 2003;17 Suppl 1:S98–S105.
32. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991;265(24):3255–3264.
33. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350(9080):757–764.
34. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting–enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145–153.
35. Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of β-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation. 2008;117(20):2706–2715.
36. Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther. 2009;85(1):86–88.
37. Morley JE. Hypertension in older patients: a complex clinical problem. Clin Geriatr Med. 2009;25(2):217–229.
38. Benetos A, Labat C, Rossignol P, et al. Treatment with multiple blood pressure medications, achieved blood pressure, and mortality in older nursing home residents. JAMA Intern Med. 2015;175(6):989–995.
39. Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo-controlled trial. Lancet Neurol. 2008;7(8):683–689.
40. American Diabetes Association. classification and diagnosis of diabetes: standards of medical care in diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S97–S110.
41. Kooman JP, Kotanko P, Schols AM, et al. Hypertension in chronic kidney disease: pathophysiological and therapeutic aspects. Clin J Am Soc Nephrol. 2020;15(2):311–322.
42. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2017;70(6):776–803.
43. Ricci F, Fedorowski A, Radico F, et al. Cardiovascular morbidity and mortality related to orthostatic hypotension: a meta-analysis of prospective observational studies. Eur Heart J. 2015;36(25):1609–1617.
44. Franklin SS, Wong ND. Hypertension and cardiovascular disease in the elderly: the Framingham Heart Study. Glob Heart. 2013;8(1):49-57.
45. Banegas JR, Ruilope LM, de la Sierra A, et al. Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med. 2018;378(16):1509–1520.
46. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46(1):156–161.
47. Stergiou GS, Ntineri A, Kollias A, et al. Home blood pressure monitoring in the 21st century. J Clin Hypertens. 2018;20(7):1116–1121.
48. Parati G, Stergiou GS, Bilo G, et al. Home blood pressure monitoring: methodology, clinical relevance and practical application. Blood Press Monit. 2008;13(2):107–115.
49. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114–1117.
50. Burnier M, Egan BM. Adherence in hypertension. Circ Res. 2019;124(7):1124–1140.
51. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399–407.
52. Carter BL, Coffey CS, Ardery G, et al. Cluster-randomized trial of a physician–pharmacist collaborative model to improve blood pressure control. Circ Cardiovasc Qual Outcomes. 2015;8(3):235–243.
53. Morgado M, Rolo S, Macedo AF, et al. Predictors of uncontrolled hypertension and antihypertensive medication nonadherence. J Cardiovasc Dis Res. 2010;1(4):196–202.
54. Omboni S, McManus RJ, Bosworth HB, et al. Evidence and recommendations on the use of telemedicine for the management of arterial hypertension: an international expert position paper. Hypertension. 2020;76(5):1368–1383.
55. Krousel-Wood M, Thomas S, Muntner P, et al. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol. 2004;19(4):357–362.
56. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338(8778):1281–1285.
57. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2. Lancet. 1999;354(9192):1751–1756.
58. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–2997.
59. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–967.
60. Juraschek SP, Daya N, Appel LJ, et al. Orthostatic hypotension, cardiovascular outcomes, and adverse events: results from SPRINT. Hypertension. 2020;75(3):660–667.
61. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65.
62. Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition—multimorbidity. JAMA. 2012;307(23):2493–2494.
63. Johnson JA, Cavallari LH. Pharmacogenetics and cardiovascular disease—implications for personalized medicine. Pharmacol Rev. 2013;65(3):987-1009.
64. Johnson JA, Cavallari LH. Pharmacogenetics and cardiovascular disease—implications for personalized medicine. Pharmacol Rev. 2013;65(3):987-1009.
65. Krittanawong C, Johnson KW, Rosenson RS, et al. Deep learning for cardiovascular medicine: a practical primer. Eur Heart J. 2019;40(25):2058–2073.
66. Cherubini A, Oristrell J, Pla X, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med. 2011;171(6):550–556.
67. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223–237.
68. Maddox TM, Januzzi JL Jr, Allen LA, et al. Virtual care in cardiology: promise and pitfalls. J Am Coll Cardiol. 2021;77(23):2931–2949.
69. Oliveros E, Patel H, Kyung S, Fugar S, Williams KA, Narayan P, Mahmud E. Hypertension in older adults: Assessment, management, and challenges. Clin Cardiol. 2020;43(2):99–107.
70. Benetos A, Petrovic M, Strandberg T. Hypertension management in older and frail older patients. Circ Res. 2019;124(7):1045–1060.
71. Dhiman P, Kaur M, Singh S, Singh S, Aggarwal HK. Hypertension in the elderly: challenges in management and treatment. Curr Hypertens Rep. 2024;26(1):1–12.
72. Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines. J Hypertens. 2020;38(6):982–1004.